Life Scientist > Health & Medical

New cancer drugs threaten to stretch PBS thin

24 September, 2013 by Dylan Bushell-Embling

Advancements in fighting cancer are also driving up the cost of cancer drugs, which could present a major strain on PBS resources, according to Flinders University’s Michael Sorich.


Bioniche to raise $10m through equity offer

20 September, 2013 by Dylan Bushell-Embling

Bioniche (ASX:BNC) has launched a $10m capital raising in Canada to ensure it has funds to continue development of cancer treatment Urocidin while it sells its animal health unit.


Creative prize for early-career researchers

19 September, 2013

Applications are open for The Centenary Institute Lawrence Creative Prize for early-career biomedical researchers.


Viralytics meets primary goal of melanoma trial

19 September, 2013 by Dylan Bushell-Embling

A phase II trial of Viralytics' (ASX:VLA) Cavatak cancer-targeting virus in late-stage melanoma is still recruiting patients but has already met its primary endpoint.


New government, no science portfolio

17 September, 2013

The incoming ministry for the newly elected Australian Government has been unveiled.


Patrys antibody gets orphan drug status in myeloma

12 September, 2013 by Dylan Bushell-Embling

Patrys's (ASX:PAB) anticancer antibody, PAT-SM6, has been granted orphan drug designation in the EU for bone marrow cancer multiple myeloma.


Starpharma developing new chemotherapy formulation

11 September, 2013 by Dylan Bushell-Embling

Starpharma (ASX:SPL) will advance dendrimer-oxaliplatin into development, after lab trials indicate its version of the chemotherapy drug can be more effective and reduces toxicity.


Viralytics cleared to begin UK cancer trial

11 September, 2013 by Dylan Bushell-Embling

The UK's MHRA has given its final approval for a phase I/II study of Viralytics' oncolytic virus in melanoma, prostate, lung or metastatic bladder cancers.


ResMed completes recruitment for heart failure trial

06 September, 2013 by Dylan Bushell-Embling

ResMed (ASX:RMD) has signed up all 1325 patients for what it is billing as the world's largest study of sleep-disordered breathing therapy in at-risk heart failure patients.


A new CEO for Dendright

05 September, 2013

Brisbane-based biotech Dendright has appointed Helen Roberts as CEO.


Telesso to raise $6.5m to fund acne drug trial

04 September, 2013 by Dylan Bushell-Embling

Shell company Telesso (ASX:TEO) aims to raise up to $6.5m to help support its plan to acquire Mimetica, take on the company's name and fund phase II trials for Mimetica's acne drug candidate.


GI Dynamics extends Australian reach of EndoBarrier

03 September, 2013 by Dylan Bushell-Embling

GI Dynamics (ASX:GID) said five new centres in Australian capital cities have agreed to offer EndoBarrier as a treatment option for type 2 diabetes and obesity.


GTG signs with new US PPO for BREVAGen

22 August, 2013

Genetic Technologies (ASX:GTG) has arranged for insurance claims for its BREVAGen breast cancer risk test to be adjudicated in-network with an eighth US PPO.


Prima cleared to extend cancer trial to Korea

22 August, 2013 by Dylan Bushell-Embling

Prima BioMed (ASX:PRR) has received approval to extend its CANVAS cancer vaccine study to South Korea, the first Asian country to be involved in the phase II/III trial.


Sitting too much?

22 August, 2013

Findings of the 12-year AusDiab follow-up study show that Australians aren’t making the lifestyle changes needed to address obesity, high blood pressure and diabetes.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd